Stock fact sheet · data as of
Cardiol Therapeutics Inc. (CRDL): fair value, margin of safety and Wheel Score
Ticker symbol CRDL · Healthcare · Drug Manufacturers - Specialty & Generic · Canada · Class A common stock · Speculative
CRDL is Cardiol Therapeutics Inc.'s Class A common stock. The classes own the same business, share the same earnings report and trade within a few cents of each other; what differs is mainly the vote each share carries - the company's annual report sets out the voting rights.
Is CRDL undervalued?
Cardiol Therapeutics Inc. (CRDL) closed at 1.01 on 5 Nov 2026, 574% above the GLS average fair value of 0.1498. 1 of the 1 models that produced a number value the shares below the current price. A gap this wide usually means the market is paying for growth or a story the trailing numbers do not show yet; the models work from filed results, not forecasts, so they are conservative by design.
The average is built from just 1 models (DCF) - the rest returned nothing because an input they need (dividends, free cash flow, book value) is zero or negative - so treat it with more caution than usual.
The nightly engine files CRDL under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for CRDL
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.1498 | -85% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.1056 | -90% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 8.00 | +692% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Cardiol Therapeutics Inc. scores only 2 of 9 on the Piotroski F-score, which fails the "Piotroski 6 or more" Wheel Trade Filter. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.1/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -187.8%, ROE -189.2%, ROA -143.2% - with debt at 0.01 times equity and negative free cash flow.
Cardiol Therapeutics Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 3/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 2 / 9 | ROIC | -187.8% |
|---|---|---|---|
| GLS Moat | 1.1 / 10 | ROE | -189.2% |
| Debt / equity | 0.01 | ROA | -143.2% |
| Free-cash-flow yield | -13.9% | Payout ratio | 0% |
| Institutions | 3 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 10: Weak
With a Wheel Score of 10 Cardiol Therapeutics Inc. sits in the Weak band. It fails filter 1, options that actually trade - options too quiet (9 open interest, 9 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades 574% above our fair value; and filter 4, financially healthy - Piotroski 2/9 (under 6); and filter 7, a premium worth selling - no implied volatility; and filter 8, big enough - market cap $122M (under $1.0B); and filter 9, not a penny stock - price 1.01 (under $5); Value (weak) is its weakest part.
No implied volatility is recorded for CRDL - the nightly snapshot found no near-the-money contracts 20-60 days out - so it fails the Wheel Trade Filter on premium. Chain open interest is thin - 9 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 870k shares a day on a market cap of $122M, with a beta of 0.52 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (9 open interest, 9 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades 574% above our fair value |
| 4 | Financially healthy | Fails | Piotroski 2/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | no implied volatility |
| 8 | Big enough | Fails | market cap $122M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 1.01 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 574% above fair value | |
| Premium | Weak | no option data | |
| Moat | Weak | moat 1.1/10 | |
| Health | Weak | Piotroski 2/9 | |
| Red Flags | Fair | Red Flags score 75/100 | |
| Option trading | Weak | 9 contracts a day, 9 open interest | |
| Stability | Fair | beta 0.52, $122M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Cardiol Therapeutics Inc. reports earnings on 12 Nov 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
No analyst upgrades or downgrades were recorded in the last 30 days.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Cardiol Therapeutics Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| BGM BGM Group Ltd. | 9.12 | 6.82 | -34% | 12No options | $116M |
| ORGO Organogenesis Holdings Inc. | 0.8700 | 4.46 | +80% | 21Weak | $112M |
| DERM Journey Medical Corporation | 4.73 | - | - | 23Weak | $134M |
| OGI Organigram Global Inc. | 0.9650 | 11.09 | +91% | 30Weak | $136M |
| AAWH Ascend Wellness Holdings, Inc. | 0.3950 | 4.21 | +91% | 25No options | $80M |
| CPIX Cumberland Pharmaceuticals Inc. | 4.44 | 22.07 | +80% | 26Weak | $67M |
| SIGA SIGA Technologies, Inc. | 3.15 | 8.74 | +64% | 35Weak | $226M |
| GLAS Glass House Brands Inc | 2.58 | 54.75 | +95% | 30Weak | $227M |
| ZYBT Zhengye Biotechnology Holding Limited | 1.37 | 1.27 | -7% | 13No options | $65M |
| LFCR Lifecore Biomedical, Inc. | 6.44 | 0.9450 | -581% | 10Weak | $244M |
| ELTP Elite Pharmaceuticals, Inc. | 0.2400 | 6.18 | +96% | 33No options | $259M |
| TLPH Talphera, Inc. | 1.05 | - | - | 13Weak | $55M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about CRDL
What kind of share is CRDL?
CRDL is Cardiol Therapeutics Inc.'s Class A common stock. The classes own the same business, share the same earnings report and trade within a few cents of each other; what differs is mainly the vote each share carries - the company's annual report sets out the voting rights.
Is CRDL undervalued right now?
No: at 1.01 the stock trades 574% above the GLS average fair value of 0.1498 (data as of 5 Nov 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of CRDL and what does it mean?
CRDL scores 10 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 3, 4, 7, 8, 9. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for CRDL?
0.1498 per share as of 5 Nov 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Cardiol Therapeutics Inc. report earnings next?
The next earnings report is due on 12 Nov 2026 (before the open), 7 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does CRDL have listed options, and how liquid are they?
Yes. The nightly snapshot found 4 listed contracts with 9 open interest across all expiries. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.